Cesca Therapeutics (KOOL) Monday reported a wider net loss for fiscal 2018 when revenues of the biotechnology firm declined sharply....
Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the...
Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after...
Exelixis (EXEL) reported Q4 earnings of 37 cents per share and revenue of $228.6 million that beat analysts’ views. Analysts...
In the current environment, investment in the biotech stocks could be a risky recommendation for the investors. Despite its erratic...
Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of...
Biotechnology company Gilead Sciences (GILD) is scheduled to report fourth-quarter earnings results after the closing bell on Monday, February 4....
Amgen (AMGN) will be reporting its fourth quarter and full-year 2018 earnings results on Tuesday, January 29 after market closes....
Life sciences company Cambrex Corp. (CBM) Wednesday completed its previously announced acquisition of Avista Pharma Solutions, a biotech firm engaged...
Avid Bioservices (CDMO) reported a narrower net loss for the second quarter of 2019, helped by a sharp decline in...
Avid Bioservices (CDMO), a contract manufacturer in the biotechnology industry, is scheduled to release its second-quarter financial results Monday after...
